Characteristics and distribution of methylation status in patients with CRC (n=132)
| Methylation status | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CDKN2A | MLH1 | MGMT | ≥1 of genes | ||||||
| Variables | Total | Normal | Tumors | Normal | Tumors | Normal | Tumors | Normal | Tumors |
| Sex, n (%) | |||||||||
| Male | 64 (48.5) | 9 (14.1) | 32 (50.0) | 1 (1.6) | 10 (15.6) | 4 (6.3) | 27 (42.2) | 13 (20.3) | 44 (68.8) |
| Female | 68 (51.5) | 13 (19.1) | 23 (33.8) | 3 (4.4) | 11 (16.2) | 5 (7.4) | 32 (47.1) | 20 (29.4) | 43 (63.2) |
| Age at surgery | |||||||||
| Mean (SD) | 66.1 (13.7) | 63.1 (16.0) | 63.2 (16.0) | 66.3 (14.8) | 59.5 (2.6) | 69.1 (13.5) | 60.1 (8.4) | 66.2 (12.9) | 62.9 (14.3) |
| <65, n (%) | 59 (44.7) | 10 (16.9) | 24 (40.7) | 4 (6.8) | 8 (13.6) | 7 (11.9) | 28 (47.5) | 18 (30.5) | 40 (67.8) |
| ≥65, n (%) | 73 (55.3) | 12 (16.4) | 30 (41.1) | 0 (0.0) | 13 (17.8) | 2 (2.7) | 30 (41.1) | 15 (20.5) | 47 (64.4) |
| Stage, n (%) | |||||||||
| I | 21 (15.9) | 5 (23.8) | 5 (23.8) | 1 (4.8) | 2 (9.5) | 1 (4.8) | 6 (28.6) | 6 (28.6) | 11 (52.4) |
| II | 49 (37.1) | 10 (20.4) | 21 (42.9) | 1 (2.0) | 11 (22.4) | 2 (4.1) | 24 (49.0) | 13 (26.5) | 35 (71.4) |
| III | 38 (28.8) | 6 (15.8) | 17 (44.7) | 2 (5.3) | 5 (13.2) | 3 (7.9) | 20 (52.6) | 10 (26.3) | 27 (71.1) |
| IV | 24 (18.2) | 3 (12.5) | 13 (54.2) | 1 (4.2) | 3 (12.5) | 3 (12.5) | 9 (37.5) | 6 (25.0) | 15 (62.5) |
| Recurrence, n (%) | |||||||||
| No | 91 (68.9) | 15 (16.5) | 34 (37.4) | 3 (3.3) | 16 (17.6) | 4 (4.4) | 42 (46.2) | 21 (23.1) | 59 (64.8) |
| Yes | 41 (31.1) | 9 (22.0) | 22 (53.7) | 2 (4.9) | 5 (12.2) | 5 (12.2) | 17 (41.5) | 14 (34.1) | 29 (70.7) |
| All-cause mortality, n (%) | |||||||||
| No | 101 (76.5) | 44 (43.6) | 12 (38.7) | 4 (4.0) | 17 (16.8) | 8 (7.9) | 48 (47.5) | 29 (28.7) | 69 (68.3) |
| Yes | 31 (23.5) | 9 (20.8) | 22 (21.4) | 1 (3.2) | 4 (12.9) | 1 (3.2) | 11 (35.5) | 6 (19.4) | 19 (61.3) |
| Adjuvant chemotherapy, n (%) | |||||||||
| No | 56 (42.4) | 12 (21.4) | 20 (35.7) | 1 (1.8) | 8 (14.3) | 2 (3.6) | 26 (46.4) | 15 (26.8) | 37 (66.1) |
| Yes | 76 (57.6) | 12 (15.8) | 36 (47.4) | 4 (5.3) | 13 (17.1) | 7 (9.8) | 33 (43.4) | 20 (26.3) | 51 (67.1) |
| Lymphovascular invasion, n (%)* | |||||||||
| No | 45 (34.1) | 7 (15.6) | 19 (42.2) | 3 (6.7) | 9 (20.0) | 3 (7.1) | 23 (51.1) | 12 (26.7) | 32 (71.1) |
| Yes | 3 (2.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (33.3) | 0 (0.0) | 1 (33.3) |
| Histological grade, n (%)* | |||||||||
| Well | 2 (1.5) | 0 (0.0) | 1 (50.0) | 1 (50.0) | 1 (50.0) | 0 (0.0) | 1 (50.0) | 1 (50.0) | 2 (100.0) |
| Moderately | 92 (69.7) | 18 (19.6) | 40 (43.5) | 4 (4.3) | 14 (15.2) | 8 (8.7) | 37 (40.2) | 26 (28.3) | 59 (64.1) |
| Poor or undifferentiated | 8 (6.1) | 1 (12.5) | 4 (50.0) | 0 (0.0) | 1 (12.5) | 0 (0.0) | 5 (62.5) | 1 (12.5) | 7 (87.5) |
| Tumor location, n (%)* | |||||||||
| Colon | 91 (68.9) | 15 (16.5) | 38 (41.8) | 5 (5.5) | 15 (16.5) | 7 (7.7) | 38 (41.8) | 24 (26.4) | 59 (64.8) |
| Rectum | 16 (12.1) | 6 (37.5) | 10 (44.9) | 0 (0.0) | 2 (12.5) | 1 (6.3) | 8 (50.0) | 6 (37.5) | 13 (81.3) |
*The total number of patients with CRC does not correspond because of missing data.
CDKN2A, cyclin-dependent kinase inhibitor 2A; CRC, colorectal cancer; MGMT, O-6-methylguanine DNA methyltransferase; MLH1, mutL homolog 1.